- Report
- February 2024
- 70 Pages
Germany
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Italy
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Oman
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
France
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
United States
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Spain
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Iran
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Russia
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Australia
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
China
From €4222EUR$4,750USD£3,664GBP
- Report
- February 2024
- 70 Pages
Japan
From €4222EUR$4,750USD£3,664GBP
- Report
- August 2023
- 150 Pages
North America
From €4222EUR$4,750USD£3,664GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4222EUR$4,750USD£3,664GBP

Dapagliflozin is a drug used to treat endocrine and metabolic disorders. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This helps to reduce blood sugar levels in people with type 2 diabetes. Dapagliflozin is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes.
Dapagliflozin is available in both tablet and oral solution form and is typically taken once daily. Common side effects include urinary tract infections, increased urination, and genital yeast infections.
The Dapagliflozin market is highly competitive, with several major pharmaceutical companies offering the drug. These include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Novo Nordisk. Show Less Read more